Brainomix 360 (formerly known as e-Stroke) helps clinical decision-making in stroke and was among more than a dozen technologies assessed by NICE, a highly respected health evaluator with a stringent evidence-based approach. Its recommendations carry global significance.
The company says the NICE guidance elevates the Brainomix 360 stroke platform, the European market leading solution now entering the US market, to an evidence-generation framework. This, it says enables stroke units across the UK to make use of the technology while further evidence is collected.
More than 100,000 strokes occur every year in the UK, making it is a leading cause of disability and one of the most common causes of early death.
Improved access to treatment using Brainomix 360
There are two main types of strokes, ischaemic and haemorrhagic strokes that affect the brain in different ways. Ischaemic strokes are the most common type of stroke. They happen when a blood clot blocks the flow of blood and oxygen to the brain. Haemorrhagic strokes are less common and happen when a blood vessel bursts and bleeds into and around the brain.
The Health Technology Assessment (HTA) acknowledged that there is evidence showing that patients admitted to the hospital with a suspected stroke had faster and improved access to treatment after using Brainomix 360. NICE has requested that further evidence be gathered to validate the significance of that link, along with cost-effectiveness data.
Dr Michalis Papadakis, co-founder and CEO of Brainomix, said: “We are very pleased to receive this endorsement from NICE, which is an acknowledgment of the critical role that our AI-powered software is playing in stroke care, helping clinicians make more confident decisions leading to more patients getting access to life saving treatments. Most importantly, this recommendation was driven by the emergence of powerful, real-world evidence demonstrating the transformative impact of Brainomix 360 on stroke treatment, mechanical thrombectomy in particular.”
NHS AI in Health & Care Award
In 2020, the company received the prestigious NHS AI in Health & Care Award in 2020 enabling its platform to be deployed across multiple UK stroke networks.
An independent evaluation by the team at Health Innovation Oxford and Thames Valley, as part of this award, has been assessing the impact of the stroke AI platform across more than 24 stroke centres and included tens of thousands of patients. This independent real-world impact evaluation will add further evidence to demonstrate the value of Brainomix 360 in the NHS.
A recent report from Health Innovation Oxford & Thames Valley (formerly known as Oxford Academic Health Science Network) found that the average thrombectomy treatment rate in hospitals with the software was 55% higher than the national average – an uplift that reflects hundreds more patients receiving life-changing thrombectomy treatment and avoiding the long-term effects of stroke.
Dr Kiruba Nagaratnam, consultant stroke physician and clinical lead for stroke medicine at the Royal Berkshire Hospital in Reading, said: “We welcome this latest guidance from NICE, which reflects the clinical value that Brainomix 360 brings to stroke care – which we have been seeing since we first implemented the software in March 2020. Our recently published study showed that the implementation of Brainomix 360 not only improved our speed of treatment but most notably, improved patient outcomes, with the number of patients achieving functional independence rising from 16% to 48%.”
The Brainomix 360 stroke platform has been widely adopted across England and is now used in the majority of stroke centres. The technology has also been deployed in more than 30 countries, including a national-level deployment in Wales and Hungary, and recently launched in the US following a series of FDA clearances.